Non-coding Cancer Biology
The Non-Coding Genome plays a fundamental role in human disease including cancer. Our goal is to gain a deeper understanding of the cancer genome’s regulatory circuitry to identify specific vulnerabilities within the non-coding genome of cancer cells.
Research
How do changes in epigenetic, transcriptional and regulatory networks facilitate malignant transformation and cancer? By answering this fundamental question we aim to build novel and highly personalized treatments and develop early detection strategies of malignant and pre-malignant states.
Methods
We use novel CRISPR tools to understand the regulatory circuitry and non-coding genome of cancer cells. This includes nuclease-dead CRISPR systems linked to a broad array of effectors as well as novel RNA-targeting CRISPR systems ideally suited to tackle the non-coding transcriptome.
About this site
Modern cancer research relies on an ever growing arsenal of advanced methods and datasets. Openly sharing these resources enhances reproducibility, accelerates dissemination of new knowledge and promotes new discoveries – all of which serve the ultimate goal of improving cancer outcomes. Along these lines, this website aims to make all our resources including code, protocols and data fully available to the research community.
Affiliations & funding
As a Junior Clinical Cooperation Unit (CCU) of the DKTK partner site Munich, we are part of the DKFZ Network. At the LMU Munich, we are part of the Institute of Pathology. Our lab is currently based at the Lab for Experimental Leukemia and Lymphoma Research (ELLF) of the Department of Medicine III.